Letram Adverse Reactions

FC tablet: The most commonly reported an undesirable effect was fatigue.
Very common undesirable effects: General disorders and administration site conditions: asthenia, fatigue.
Nervous system disorders: somnolence, headache.
Common undesirable effects: Blood disorders: thrombocytopenia.
Gastrointestinal disorders: abdominal pain, diarrhoea, dyspepsia, nausea, vomiting.
Nervous system disorders: convulsion, dizziness, tremor, balance disorder, memory impairment.
Psychiatric disorders: aggression, depression, hostility, insomnia, irritability, nervousness.
Metabolism and nutrition disorders: anorexia.
Ear and labyrinth disorders: vertigo.
Eye disorders: diplopia, vision blurred.
Infections and infestations: infection, nasopharyngitis.
Respiratory, thoracic and mediastinal disorders: cough.
Musculoskeletal and connective tissue disorders: Muscular weakness, myalgia.
Rare: Rhabdomyolysis and blood creatine phosphokinase increased.
Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.
Cases of encephalopathy have been rarely observed after levetiracetam administration. These undesirable effects generally occurred at the beginning of the treatment (few days to a few months) and were reversible after treatment discontinuation.
Renal & urinary disorders: Acute kidney injury.
Skin and subcutaneous tissue disorders: rash.
Description of selected adverse reactions: The risk of anorexia is higher when topiramate is coadministered with Levetiracetam. In several cases of alopecia, recovery was observed when Levetiracetam was discontinued.
Bone marrow suppression was identified in some of the cases of pancytopenia.